ES2509820T3 - Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer - Google Patents

Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer Download PDF

Info

Publication number
ES2509820T3
ES2509820T3 ES07857632.9T ES07857632T ES2509820T3 ES 2509820 T3 ES2509820 T3 ES 2509820T3 ES 07857632 T ES07857632 T ES 07857632T ES 2509820 T3 ES2509820 T3 ES 2509820T3
Authority
ES
Spain
Prior art keywords
alkyl
optionally substituted
heterocyclyl
branched
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07857632.9T
Other languages
English (en)
Inventor
Tiziano Bandiera
Andrea Lombardi Borgia
Marcella Nesi
Ettore Perrone
Roberto Bossi
Paolo Polucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Application granted granted Critical
Publication of ES2509820T3 publication Critical patent/ES2509820T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I): en el que: Ar es arilo opcionalmente sustituido con uno o mas sustituyentes elegidos independientemente entre halOgeno, alquenilo, alquinilo, ciano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, 0R7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10, R8R9N-alquilo C1-C6, R80-alquilo C1-C6, un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo y arilo, en los que: R4 es hidrOgeno, alquenilo, alquinilo, NR5R6, 0R7, SR7, R8R9N-alquilo Ci-C6, R80-alquilo C1-C6, un alquilo Ci-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo; R5 y R6 son independientemente hidrógeno, alquenilo, alquinilo, R8R9N-alquilo C2-C6, R80-alquilo C2-C6, un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo, o R5 y R6, tomados junto con el atomo de nitrógeno al que estan unidos pueden formar un grupo heterociclilo opcionalmente sustituido; R7 es hidrogeno, alquenilo, alquinilo, COR4, SOR10, SO2R10, R8R9N-alquilo C2-C6, R80-alquilo C2-C6, un alquilo Ci-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo, donde R4 es como se ha definido anteriormente; R8 y R9 son independientemente hidr6geno, alquenilo, alquinilo, COR4, un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo, o R8 y R9, tomados junto con el atomo de nitrogeno al que estan unidos, pueden formar un grupo heterociclilo opcionalmente sustituido, donde R4 es como se ha definido anteriormente; R10 es hidrOgeno, alquenilo, alquinilo, NR5R6, 0R7, R8R9N-alquilo Ci-C6, R80-alquilo Ci-C6, un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo, donde R5, R6, R7, R8 y R9 son como se han definido anteriormente; R es un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, cicloalquilo C3-C6, heterociclilo o arilo; R1, R2 y R3 son independientemente hidrógeno, halogeno, nitro, un alquilo C1-C6 lineal o ramificado opcionalmente sustituido adicionalmente, NR5R6 u 0R7, donde R5, R6 y R7 son corm se han definido anteriormente; y una de sus sales farmaceuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
ES07857632.9T 2006-12-20 2007-12-14 Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer Active ES2509820T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06126701 2006-12-20
EP06126701 2006-12-20
PCT/EP2007/063998 WO2008074749A1 (en) 2006-12-20 2007-12-14 Indazole derivatives as kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2509820T3 true ES2509820T3 (es) 2014-10-20

Family

ID=39245139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07857632.9T Active ES2509820T3 (es) 2006-12-20 2007-12-14 Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer

Country Status (15)

Country Link
US (1) US8114865B2 (es)
EP (1) EP2120932B1 (es)
JP (1) JP5302896B2 (es)
CN (1) CN101594862B (es)
AU (1) AU2007336335B8 (es)
BR (1) BRPI0720589A2 (es)
CA (1) CA2673095C (es)
DK (1) DK2120932T3 (es)
EA (1) EA017852B1 (es)
ES (1) ES2509820T3 (es)
MX (1) MX2009006401A (es)
PL (1) PL2120932T3 (es)
PT (1) PT2120932E (es)
SI (1) SI2120932T1 (es)
WO (1) WO2008074749A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101754962B (zh) * 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、***和四唑衍生物
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
EP2373626B1 (en) * 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
CN102666553B (zh) 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EA201290919A1 (ru) * 2010-03-16 2013-03-29 Дана-Фарбер Кэнсер Инститьют, Инк. Индазольные соединения и их применение
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
US9408850B2 (en) * 2011-05-12 2016-08-09 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
CN104220442B (zh) * 2012-04-05 2016-11-23 内尔维阿诺医学科学有限公司 烷化剂
ES2771100T3 (es) * 2012-05-23 2020-07-06 Nerviano Medical Sciences Srl Proceso para la preparación de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
KR101936851B1 (ko) * 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
DK2888010T3 (da) 2012-08-22 2021-06-28 Univ Cornell Fremgangsmåder til at hæmme fascin
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015110467A1 (en) * 2014-01-23 2015-07-30 Nerviano Medical Sciences S.R.L. Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides
TWI672141B (zh) * 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6691869B2 (ja) * 2014-02-20 2020-05-13 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
KR102595599B1 (ko) * 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN104530045A (zh) * 2015-01-14 2015-04-22 中国药科大学 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
CN111225913B (zh) 2017-08-16 2024-05-31 范德比尔特大学 作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN110452176A (zh) * 2018-05-07 2019-11-15 四川大学 吲唑类衍生物及其制备方法和用途
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432416B1 (en) * 2001-09-26 2011-01-19 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
WO2004078116A2 (en) * 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1853590A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CL2009001158A1 (es) * 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.

Also Published As

Publication number Publication date
SI2120932T1 (sl) 2014-09-30
AU2007336335B8 (en) 2014-07-24
EA200970595A1 (ru) 2010-02-26
AU2007336335A1 (en) 2008-06-26
MX2009006401A (es) 2009-06-23
US8114865B2 (en) 2012-02-14
AU2007336335A8 (en) 2014-07-24
PT2120932E (pt) 2014-10-10
DK2120932T3 (da) 2014-10-13
AU2007336335A2 (en) 2009-08-06
JP5302896B2 (ja) 2013-10-02
EP2120932B1 (en) 2014-07-09
BRPI0720589A2 (pt) 2014-02-25
CN101594862B (zh) 2015-11-25
EA017852B1 (ru) 2013-03-29
US20100197665A1 (en) 2010-08-05
AU2007336335B2 (en) 2013-05-30
EP2120932A1 (en) 2009-11-25
JP2010530840A (ja) 2010-09-16
CA2673095C (en) 2016-03-15
CN101594862A (zh) 2009-12-02
WO2008074749A9 (en) 2009-05-07
WO2008074749A1 (en) 2008-06-26
PL2120932T3 (pl) 2015-02-27
CA2673095A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
ES2624795T3 (es) Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR044796A1 (es) Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
CO5720994A2 (es) Derivados sustituidos del pirrol
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR054831A1 (es) Derivados de heptaazafenaleno, procedimientos para su obtencion, asi como utilizacion de los mismos como agentes protectores contra la radiacion uv